^
    Back
    Association details:
    Biomarker:TFE3 rearrangement + MET expression
    Cancer:Soft Tissue Sarcoma
    Drug:Xalkori (crizotinib) (ALK inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: C3 – Early Trials
    New
    Source:
    ASCO 2018
    Title:

    Activity and safety of crizotinib in patients with advanced, metastatic alveolar soft part sarcoma (ASPS) with rearrangement of TFE3: European Organization for Research and Treatment of Cancer (EORTC) phase 2 trial 90101 CREATE.

    Published date:
    05/16/2018
    Excerpt:
    ...patients with advanced, metastatic alveolar soft part sarcoma (ASPS)...that crizotinib has activity in TFE3 rearranged ASPS. Among 40 MET+ pts, 1 achieved a confirmed partial response (PR) lasting 215 d and 35 had stable disease (SD) (ORR: 2.5%, 95%CI: 0.6-80.6%). Further efficacy endpoints in MET+ cases were: DCR 90.0% (76.3-97.2%); 1-year PFR 37.5% (22.9-52.1%); 1-year OSR 97.4% (82.8-99.6%).
    DOI:
    10.1200/JCO.2018.36.15_suppl.11540
    Trial ID:
    NCT01524926